Letteratura scientifica selezionata sul tema "Philip Johnson Associates"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Indice
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Philip Johnson Associates".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Philip Johnson Associates"
Chohan, S., A. Kavanaugh, V. Strand, R. C. Chou, A. M. Mendelsohn, S. Rozzo e P. J. Mease. "AB0803 EFFICACY OF TILDRAKIZUMAB IN PsA: DAS28-CRP SCORES THROUGH WEEK 52". Annals of the Rheumatic Diseases 79, Suppl 1 (giugno 2020): 1702–3. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3907.
Testo completoJayne, D., P. Gavin, E. Allman, C. Di Poto, X. Tian, S. Hess, M. Ramaswamy et al. "OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS". Annals of the Rheumatic Diseases 82, Suppl 1 (30 maggio 2023): 90.1–90. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1569.
Testo completoPray, C., N. Narula, E. C. Wong, J. K. Marshall, S. Rangarajan, S. Islam, A. Bahonar et al. "A176 ASSOCIATIONS OF ANTIBIOTICS, HORMONAL THERAPIES, ORAL CONTRACEPTIVES, AND LONG-TERM NSAIDS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE PROSPECTIVE URBAN RURAL EPIDEMIOLOGY (PURE) STUDY". Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (1 marzo 2023): 20–22. http://dx.doi.org/10.1093/jcag/gwac036.176.
Testo completoRahman, P., C. T. Ritchlin, P. Helliwell, W. H. Boehncke, P. J. Mease, A. B. Gottlieb, S. Kafka et al. "FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS". Annals of the Rheumatic Diseases 79, Suppl 1 (giugno 2020): 776–77. http://dx.doi.org/10.1136/annrheumdis-2020-eular.387.
Testo completoRahman, P., P. J. Mease, A. Deodhar, A. Kavanaugh, S. D. Chakravarty, A. Kollmeier, Y. Liu, M. Shawi e C. Han. "OP0025 FACTORS ASSOCIATED WITH FATIGUE AND ITS IMPROVEMENT – A PRINCIPAL COMPONENT ANALYSIS OF PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS FROM GUSELKUMAB PHASE 3 TRIALS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 maggio 2022): 18–19. http://dx.doi.org/10.1136/annrheumdis-2022-eular.895.
Testo completoCoates, L. C., C. T. Ritchlin, L. Gossec, P. Helliwell, P. Rahman, E. C. Hsia, A. Kollmeier et al. "POS1024 GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS". Annals of the Rheumatic Diseases 80, Suppl 1 (19 maggio 2021): 781–82. http://dx.doi.org/10.1136/annrheumdis-2021-eular.167.
Testo completoCurtis, J., I. Mcinnes, D. D. Gladman, F. Yang, S. Peterson, P. Agarwal, A. Kollmeier et al. "POS1028 PATIENT CHARACTERISTICS & CLINICAL FEATURES ASSOCIATE WITH HEALTH-RELATED QUALITY OF LIFE IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY". Annals of the Rheumatic Diseases 80, Suppl 1 (19 maggio 2021): 784–85. http://dx.doi.org/10.1136/annrheumdis-2021-eular.432.
Testo completoCoates, L., J. Ramírez, D. Mcgonagle, S. Aydin, M. Zimmermann, F. Nantel, M. Shawi, E. Rampakakis, P. Nash e P. J. Mease. "POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY". Annals of the Rheumatic Diseases 82, Suppl 1 (30 maggio 2023): 1137.1–1137. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2581.
Testo completoMcgonagle, D., I. Mcinnes, A. Deodhar, G. Schett, P. J. Mease, M. Shawi, S. Kafka et al. "AB0801 EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES". Annals of the Rheumatic Diseases 79, Suppl 1 (giugno 2020): 1701.2–1701. http://dx.doi.org/10.1136/annrheumdis-2020-eular.836.
Testo completoCurtis, J., I. McInnes, P. Rahman, D. D. Gladman, F. Yang, S. Peterson, A. Kollmeier et al. "AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2". Annals of the Rheumatic Diseases 81, Suppl 1 (23 maggio 2022): 1563.2–1564. http://dx.doi.org/10.1136/annrheumdis-2022-eular.733.
Testo completoLibri sul tema "Philip Johnson Associates"
Architecture's odd couple: Frank Lloyd Wright and Philip Johnson. 2016.
Cerca il testo completo